217 related articles for article (PubMed ID: 4090907)
1. Lack of plasma prolactin response to intravenously injected vasoactive intestinal polypeptide in patients with prolactin-secreting adenoma.
Kaji H; Chihara K; Kita T; Kashio Y; Okimura Y; Fujita T
Acta Endocrinol (Copenh); 1985 Dec; 110(4):445-50. PubMed ID: 4090907
[TBL] [Abstract][Full Text] [Related]
2. Role of vasoactive intestinal polypeptide (VIP) in regulating the pituitary function in man.
Kato Y; Shimatsu A; Matsushita N; Ohta H; Imura H
Peptides; 1984; 5(2):389-94. PubMed ID: 6089138
[TBL] [Abstract][Full Text] [Related]
3. Effect of vasoactive intestinal polypeptide (VIP) on growth hormone (GH) and prolactin (PRL) release and cell morphology in human pituitary adenoma cell cultures.
Fazekas I; Bácsy E; Varga I; Slowik F; Bálint K; Pásztor E; Czirják S; Gláz E
Folia Histochem Cytobiol; 2000; 38(3):119-27. PubMed ID: 10970071
[TBL] [Abstract][Full Text] [Related]
4. Anomalous growth hormone response to vasoactive intestinal peptide and peptide histidine methionine in patients with prolactinoma or hypothalamic hyperprolactinemia.
Watanobe H; Tamura T; Takahashi K
Neuropeptides; 1994 Aug; 27(2):137-42. PubMed ID: 7991068
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the responses in the nomifensine test with hyperprolactinemia due to prolactin-secreting pituitary tumors and nonprolactin-secreting hypothalamic tumors.
Kamoi K; Tchuchida I; Sato H; Tanaka R; Ishiguro T; Kaneko K; Iwasaki Y; Shibata A
J Clin Endocrinol Metab; 1981 Dec; 53(6):1285-7. PubMed ID: 7298805
[TBL] [Abstract][Full Text] [Related]
6. Prolactin secretion by mixed ACTH-prolactin pituitary adenoma cells in culture.
Yamaji T; Ishibashi M; Teramoto A; Fukushima T
Acta Endocrinol (Copenh); 1985 Apr; 108(4):456-63. PubMed ID: 2859725
[TBL] [Abstract][Full Text] [Related]
7. Prolactin and growth hormone responses to dermorphin in patients with prolactin-secreting pituitary adenoma.
degli Uberti EC; Trasforini G; Salvadori S; Margutti A; Rotola C; Bianconi M; Teodori V; Tomatis R; Pansini R
Metabolism; 1985 Sep; 34(9):874-9. PubMed ID: 4033428
[TBL] [Abstract][Full Text] [Related]
8. Effect of [Asu1,7]eel calcitonin on prolactin release in normal subjects and patients with prolactinoma.
Kaji H; Chihara K; Minamitani N; Kodama H; Kita T; Fujita T
Acta Endocrinol (Copenh); 1985 Mar; 108(3):297-304. PubMed ID: 3920850
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of dopaminergic tone in hyperprolactinemia. III. Thyroid-stimulating hormone response to metoclopramide in differential diagnosis and postoperative follow-up of prolactinoma patients.
De Marinis L; Mancini A; Minnielli S; Masala R; Anile C; Maira G; Barbarino A
Metabolism; 1985 Oct; 34(10):917-22. PubMed ID: 4046835
[TBL] [Abstract][Full Text] [Related]
10. Distinctive features of prolactin secretion in acromegalic patients with hyperprolactinaemia.
Serri O; Robert F; Comtois R; Jilwan N; Beauregard H; Hardy J; Somma M
Clin Endocrinol (Oxf); 1987 Oct; 27(4):429-36. PubMed ID: 3124991
[TBL] [Abstract][Full Text] [Related]
11. Vasoactive intestinal polypeptide and dopamine: effect on prolactin secretion in normal women and patients with microprolactinomas.
Conti A; Togni E; Travaglini P; Muratori M; Faglia G
Neuroendocrinology; 1987 Sep; 46(3):241-5. PubMed ID: 3658111
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of two inhibitory tests (nomifensine and L-dopa + carbidopa) for the diagnosis of hyperprolactinaemic states.
Moriondo P; Travaglini P; Nissim M; Faglia G
Clin Endocrinol (Oxf); 1980 Dec; 13(6):525-33. PubMed ID: 7226570
[TBL] [Abstract][Full Text] [Related]
13. Prolactin response to thyrotropin-releasing hormone (TRH) in patients with hypothalamic-pituitary disease.
Barbieri RL; Cooper DS; Daniels GH; Nathan D; Klibanski A; Ridgway EC
Fertil Steril; 1985 Jan; 43(1):66-73. PubMed ID: 3917409
[TBL] [Abstract][Full Text] [Related]
14. Prolactin-secreting pituitary adenomas: prolactin dynamics before and after transsphenoidal surgery.
Barbarino A; de Marinis L; Menini E; Anile C; Maira G
Acta Endocrinol (Copenh); 1979 Jul; 91(3):397-409. PubMed ID: 112818
[TBL] [Abstract][Full Text] [Related]
15. Evidence for a synergistic effect of somatostatin on vasoactive intestinal polypeptide-induced prolactin release in the rat: comparison with its effect on thyrotropin (TSH)-releasing hormone-stimulated TSH release.
Michalkiewicz M; Suzuki M; Kato M
Endocrinology; 1987 Jul; 121(1):371-7. PubMed ID: 2885177
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal polypeptide (VIP) selectively stimulates prolactin release in healthy women.
Falsetti L; Zanagnolo V; Gastaldi A; Memo M; Missale C; Spano PF
Gynecol Endocrinol; 1988 Mar; 2(1):11-8. PubMed ID: 3140588
[TBL] [Abstract][Full Text] [Related]
17. Prolactin dynamics in patients with non-secretin tumours of the hypothalamic-pituitary region.
Barbarino A; De Marinis L; Mancini A; Menini E; D'Amico C; Passeri M; Sambo P; Anile C; Maira G
Acta Endocrinol (Copenh); 1985 Sep; 110(1):10-6. PubMed ID: 3929517
[TBL] [Abstract][Full Text] [Related]
18. Antisera to vasoactive intestinal polypeptide inhibit basal prolactin release from dispersed anterior pituitary cells.
Hagen TC; Arnaout MA; Scherzer WJ; Martinson DR; Garthwaite TL
Neuroendocrinology; 1986; 43(6):641-5. PubMed ID: 3762862
[TBL] [Abstract][Full Text] [Related]
19. Benserazide and nomifensine in the diagnosis of prolactin-secreting pituitary adenomas.
Pontiroli AE; Loda G; Roggia A; Scagliola P; Falsetti L
Acta Endocrinol (Copenh); 1982 Oct; 101(2):171-9. PubMed ID: 7136447
[TBL] [Abstract][Full Text] [Related]
20. Prolactin gene expression and secretion during pregnancy and lactation in the rat: role of dopamine and vasoactive intestinal peptide.
Escalada J; Cacicedo L; Ortego J; Melian E; Sánchez-Franco F
Endocrinology; 1996 Feb; 137(2):631-7. PubMed ID: 8593812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
